No convincing evidence suggests that atypical antipsychotic medications are superior to typical medications for the treatment of adolescents with psychosis .
However , atypical antipsychotic medications may be more acceptable to young people because fewer symptomatic adverse effects are seen in the short term .
Little evidence is available to support the superiority of one atypical antipsychotic medication over another , but side effect profiles are different for different medications .
Treatment with olanzapine , risperidone and clozapine is often associated with weight gain .
Aripiprazole is not associated with increased prolactin or with dyslipidaemia .
Adolescents may respond better to st and ard-dose as opposed to lower-dose risperidone , but for aripiprazole and ziprasidone , lower doses may be equally effective .
BACKGROUND Schizophrenia often presents in adolescence , but current treatment guidelines are based largely on studies of adults with psychosis .
Over the past decade , the number of studies on treatment of adolescent-onset psychosis has increased .
The current systematic review collates and critiques evidence obtained on the use of various atypical antipsychotic medications for adolescents with psychosis .
OBJECTIVES To investigate the effects of atypical antipsychotic medications in adolescents with psychosis .
We review ed in separate analyses various comparisons of atypical antipsychotic medications with placebo or a typical antipsychotic medication or another atypical antipsychotic medication or the same atypical antipsychotic medication but at a lower dose .
Obsessive-Compulsive Symptoms in a Randomized, Double-Blind Study With Olanzapine or Risperidone in Young Patients With Early Psychosis
Background : The prevalence of obsessive-compulsive symptoms ( OCS ) in patients with schizophrenia is relatively high . Antipsychotics have been found to influence OCS . Objective : To determine whether induction or severity of OCS differs during treatment with olanzapine or risperidone in young patients with early psychosis . Methods : One hundred twenty-two patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition diagnosis of schizophrenia , schizoaffective disorder , or schizophreniform disorder were r and omized in a double-blind design to groups of 6 weeks ' treatment with olanzapine ( n = 59 ) or risperidone ( n = 63 ) , with a mean dose of 11.3 mg olanzapine and 3.0 mg risperidone at 6 weeks . Primary outcome measures were the mean baseline-to-endpoint change in total score on the Yale-Brown Obsessive-Compulsive Scale ( Y-BOCS ) . Results : Treatment with olanzapine was associated with greater decreases in Y-BOCS total score than treatment with risperidone in total group ( N = 122 : -2.2 vs -0.3 , z = -2.651 , P < 0.01 ) , in patients with baseline Y-BOCS total score greater than 0 ( n = 58 : -5.1 vs -0.4 , z = -2.717 , P < 0.01 ) , and in patients with baseline Y-BOCS total score greater than 10 ( n = 29 : -7.1 vs -0.6 , z = -2.138 , P = 0.032 ) . Conclusions : In this r and omized , 6-week , double-blind trial , we found a significant and clinical ly relevant difference in decrease in Y-BOCS scores favoring olanzapine compared with risperidone
No convincing evidence suggests that atypical antipsychotic medications are superior to typical medications for the treatment of adolescents with psychosis .
However , atypical antipsychotic medications may be more acceptable to young people because fewer symptomatic adverse effects are seen in the short term .
Little evidence is available to support the superiority of one atypical antipsychotic medication over another , but side effect profiles are different for different medications .
Treatment with olanzapine , risperidone and clozapine is often associated with weight gain .
Aripiprazole is not associated with increased prolactin or with dyslipidaemia .
Adolescents may respond better to st and ard-dose as opposed to lower-dose risperidone , but for aripiprazole and ziprasidone , lower doses may be equally effective .
BACKGROUND Schizophrenia often presents in adolescence , but current treatment guidelines are based largely on studies of adults with psychosis .
Over the past decade , the number of studies on treatment of adolescent-onset psychosis has increased .
The current systematic review collates and critiques evidence obtained on the use of various atypical antipsychotic medications for adolescents with psychosis .
OBJECTIVES To investigate the effects of atypical antipsychotic medications in adolescents with psychosis .
We review ed in separate analyses various comparisons of atypical antipsychotic medications with placebo or a typical antipsychotic medication or another atypical antipsychotic medication or the same atypical antipsychotic medication but at a lower dose .